Foundayo
(Orforglipron)Phase 3Small molecule
Eli LillyFoundayo is a small molecule that works as a GLP-1 Receptor Agonist.[2] It is being investigated across 16 indications, with its most advanced program in Phase 3.[1]
Foundayo is one of 392 small molecule programs targeting Hepatic failure. It is currently in Phase 3.
16
Indications
31
Total Trials
17
Active Trials
391
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Lovaza
AstraZenecaPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes9 trials
Show 6 more trials
Overweight7 trials
Show 4 more trials
Hypertension3 trials
Interaction3 trials
7 more indications
Obstructive Sleep Apnea1 trial
Obesity1 trial
ART1 trial
Atherosclerosis Cardiovascular Disease1 trial
Osteoarthritis1 trial
Regulatory
FDA Approval Timeline[4]
Apr 1, 2026
FOUNDAYO
NDA NDA220934
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Orforglipron. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
- [7]